We report a 25-year-old man with bradycardia after administration of ophthalmic timolol. The patient was asymptomatic, and his bradycardia resolved after stopping the eye drop. He was discharged after a four-hour observation. This case demonstrated that topical timolol eye drop may cause systemic adverse reaction. The use of timolol and its possible side-effects are discussed.
GrossR.L., PineyroA.Current use of ophthalmic beta blockers. J Glaucoma1997; 6(3): 188–91.
2.
HeelR.C., BrogdenR.N., SpeightT.M., AveryG.S.Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs1979; 17(1): 38–55.
3.
AlwardW.L.Medical management of glaucoma. N Engl J Med1998; 339(18): 1298–307.
4.
FlomenbaumN.E., editor. Goldfrank's toxicologic emergencies. 8th ed. New York: McGraw-Hill; 2006. p. 331–2.
5.
EverittD.E., AvornJ.Systemic effects of medications used to treat glaucoma. Ann Intern Med1990; 112(2): 120–5.
6.
StewartW.C., CastelliW.P.Systemic side effects of topical beta-adrenergic blockers. Clin Cardiol1996; 19(9): 691–7.
7.
UusitaloH., NiñoJ., TahvanainenK., TurjanmaaV., RopoA., TuominenJ.Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand2005; 83(6): 723–8.
MinishT., HerdA.Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report. J Emerg Med2002; 22(3): 247–9.
10.
LinkewichJ.A., HerlingI.M.Bradycardia and congestive heart failure associated with ocular timolol maleate. Am J Hosp Pharm1981; 38(5): 699–701.
11.
AnguitaM., TorresF., GimenezD., SeguraJ., AumenteD., Suarez de LezoJ.[Bradyarrhythmias secondary to the use of ophthalmic timolol. A report of 3 cases]. [Spanish]. Rev Esp Cardiol1992; 45(1): 71–3.
12.
SharifiM., KochJ.M., SteeleR.J., AdlerD., PompiliV.J., SopkoJ.Third degree AV block due to ophthalmic timolol solution. Int J Cardiol2001; 80(2-3): 257–9.
VuoriM.L., Ali-MelkkiläT., KailaT., IisaloE., SaariK.M.Plasma and aqueous humour concentrations and systemic effects of topical betaxolol and timolol in man. Acta Ophthalmol (Copenh)1993; 71(2): 201–6.
18.
NieminenT., UusitaloH., TurjanmaaV., BjärnhallG., HedenstromH., MäenpääJ.Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol2005; 61(5-6): 369–74. Epub 2005 May 24.
LustgartenJ.S., PodosS.M.Topical timolol and the nursing mother. Arch Ophthalmol1983; 101(9): 1381–2.
21.
OhnoY., IgaT., YamadaY., NagaharaM., AraieM., TakayanagiR.Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). Curr Eye Res2005; 30(4): 319–28.
22.
DicksteinK., HapnesR., AarslandT.Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol2001; 132(5): 626–32.
23.
ZimmermanT.J., KaufmanH.E.Timolol, dose response and duration of action. Arch Ophthalmol1977; 95(4): 605–7.
24.
TintinalliJ.E., KelenG.D., StapczynskiJ.S., editors. Emergency medicine: a comprehensive study guide, 5th ed. New York: McGraw-Hill; 2000. p. 172–3.
25.
WyattJ.P., IllingworthR., GrahamC., ClancyM., RobertsonC.Oxford handbook of emergency medicine, 3rd ed. Oxford; New York: Oxford University Press; 2006. p. 82–3.
26.
VuoriM.L., KailaT.Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol1995; 233(3): 131–4.
